CONTEXT: - The oncolytic polio-rhinovirus recombinant (PVSRIPO) has demonstrated promise in currently ongoing phase I/II clinical trials against recurrent glioblastoma and was granted breakthrough therapy designation by the Food and Drug Administration/Center for Biologics Evaluation and Research. A reliable clinical assay to document expression of the poliovirus receptor, CD155, in routinely available patient tumor samples is needed for continued clinical development of PVSRIPO oncolytic immunotherapy in primary brain tumors and beyond. OBJECTIVES: - To validate a novel anti-CD155 antibody for immunohistochemistry and develop a robust, reliable, and specific protocol for detecting CD155 expression in glioblastoma formalin-fixed, paraffin-embedded (FFPE) tissue samples. To characterize the expression of CD155 in human glioblastoma cells as well as to evaluate the influence of CD155 expression levels on tumor cell susceptibility to PVSRIPO infection and killing. DESIGN: - Immunohistochemical staining on glioblastoma FFPE tissue sections and immunoblot of corresponding frozen tissues were performed. Positive controls were confirmed sites of poliovirus propagation, spinal cord anterior horn, and tonsils; negative controls were vascular smooth muscle in patient samples and FFPE sections from a confirmed CD155-negative Burkitt lymphoma line (Raji). RESULTS: - We succeeded in developing a reliable assay to specifically detect CD155 by immunohistochemistry in glioblastoma FFPE sections. Our data suggest widespread, virtually universal expression of CD155 in glioblastoma cells at levels commensurate with susceptibility to PVSRIPO infection and killing. CONCLUSIONS: - Anti-CD155 antibody D3G7H achieves monospecific detection of CD155 in immunoblots of tumor homogenates and immunohistochemistry of tumor FFPE sections. Our assay has utility in defining appropriate use of PVSRIPO in oncolytic immunotherapy against malignant glioma and other cancer histotypes.
CONTEXT: - The oncolytic polio-rhinovirus recombinant (PVSRIPO) has demonstrated promise in currently ongoing phase I/II clinical trials against recurrent glioblastoma and was granted breakthrough therapy designation by the Food and Drug Administration/Center for Biologics Evaluation and Research. A reliable clinical assay to document expression of the poliovirus receptor, CD155, in routinely available patienttumor samples is needed for continued clinical development of PVSRIPO oncolytic immunotherapy in primary brain tumors and beyond. OBJECTIVES: - To validate a novel anti-CD155 antibody for immunohistochemistry and develop a robust, reliable, and specific protocol for detecting CD155 expression in glioblastomaformalin-fixed, paraffin-embedded (FFPE) tissue samples. To characterize the expression of CD155 in humanglioblastoma cells as well as to evaluate the influence of CD155 expression levels on tumor cell susceptibility to PVSRIPO infection and killing. DESIGN: - Immunohistochemical staining on glioblastoma FFPE tissue sections and immunoblot of corresponding frozen tissues were performed. Positive controls were confirmed sites of poliovirus propagation, spinal cord anterior horn, and tonsils; negative controls were vascular smooth muscle in patient samples and FFPE sections from a confirmed CD155-negative Burkitt lymphoma line (Raji). RESULTS: - We succeeded in developing a reliable assay to specifically detect CD155 by immunohistochemistry in glioblastoma FFPE sections. Our data suggest widespread, virtually universal expression of CD155 in glioblastoma cells at levels commensurate with susceptibility to PVSRIPO infection and killing. CONCLUSIONS: - Anti-CD155 antibody D3G7H achieves monospecific detection of CD155 in immunoblots of tumor homogenates and immunohistochemistry of tumor FFPE sections. Our assay has utility in defining appropriate use of PVSRIPO in oncolytic immunotherapy against malignant glioma and other cancer histotypes.
Authors: Javier G Casado; Graham Pawelec; Sara Morgado; Beatriz Sanchez-Correa; Elena Delgado; Inmaculada Gayoso; Esther Duran; Rafael Solana; Raquel Tarazona Journal: Cancer Immunol Immunother Date: 2009-03-04 Impact factor: 6.968
Authors: Michael C Brown; Elena Y Dobrikova; Mikhail I Dobrikov; Ross W Walton; Sarah L Gemberling; Smita K Nair; Annick Desjardins; John H Sampson; Henry S Friedman; Allan H Friedman; Douglas S Tyler; Darell D Bigner; Matthias Gromeier Journal: Cancer Date: 2014-06-17 Impact factor: 6.860
Authors: Melinda K Merrill; Guenter Bernhardt; John H Sampson; Carol J Wikstrand; Darell D Bigner; Matthias Gromeier Journal: Neuro Oncol Date: 2004-07 Impact factor: 12.300
Authors: Peter Tomasec; Eddie C Y Wang; Andrew J Davison; Borivoj Vojtesek; Melanie Armstrong; Cora Griffin; Brian P McSharry; Rebecca J Morris; Sian Llewellyn-Lacey; Carole Rickards; Akio Nomoto; Christian Sinzger; Gavin W G Wilkinson Journal: Nat Immunol Date: 2005-01-09 Impact factor: 25.606
Authors: Christopher S Hong; Juan C Vasquez; Adam J Kundishora; Aladine A Elsamadicy; Jason M Beckta; Amrita Sule; Asher M Marks; Nalin Leelatian; Anita Huttner; Ranjit S Bindra; Michael L DiLuna; Kristopher T Kahle; E Zeynep Erson-Omay Journal: NPJ Genom Med Date: 2020-06-01 Impact factor: 8.617
Authors: Millena Prata Jammal; Márcia Antoniazi Michelin; Rosekeila Simões Nomelini; Eddie Fernando Candido Murta Journal: Ann Transl Med Date: 2018-09
Authors: Annick Desjardins; Matthias Gromeier; James E Herndon; Nike Beaubier; Dani P Bolognesi; Allan H Friedman; Henry S Friedman; Frances McSherry; Andrea M Muscat; Smita Nair; Katherine B Peters; Dina Randazzo; John H Sampson; Gordana Vlahovic; William T Harrison; Roger E McLendon; David Ashley; Darell D Bigner Journal: N Engl J Med Date: 2018-06-26 Impact factor: 91.245
Authors: Eric M Thompson; Michael Brown; Elena Dobrikova; Vijay Ramaswamy; Michael D Taylor; Roger McLendon; Jennifer Sanks; Vidya Chandramohan; Darell Bigner; Matthias Gromeier Journal: J Neuropathol Exp Neurol Date: 2018-08-01 Impact factor: 3.685